BOEHRINGER-INGELHEIM
14.10.2020 14:02:35 CEST | Business Wire | Press release
Boehringer Ingelheim and Oxford BioTherapeutics Ltd. (OBT) today announced they are building on their successful partnership and are establishing a new alliance to discover additional selective targets for strategic cancer indications to deliver first-in-class treatments for cancer patients. Boehringer Ingelheim will use OBT’s OGAP® platform to identify novel target opportunities for new immunotherapies utilizing their T-cell engager, cancer vaccine and oncolytic virus platforms. This follows the initiation of the first patient dosing in a Phase 1 clinical trial of a bispecific antibody for the treatment of patients with small cell lung carcinoma and other neoplasms, where the target for the bispecific antibody was discovered during the first phase of the partnership.
“This collaboration with Oxford BioTherapeutics is important for advancing therapeutic modalities that depend upon the identification of unique and specific tumor antigens within our cancer immunology portfolio,” said Jonathon Sedgwick, Ph.D., Senior Vice President and Global Head Cancer Immunology & Immune Modulation Research at Boehringer Ingelheim. “We are committed to developing innovative, efficacious and safe treatment options for patients suffering from cancer, and these novel cancer target discoveries are a key step in the development of new potential treatments.”
“We view the hopeful discovery of additional tumor targets as further confirmation of the value of our OGAP® platform to identify novel targets that can be substrates for innovative new therapies,” said Christian Rohlff, Ph.D., Chief Executive Officer of OBT. “OBT’s platforms are designed to discover and validate novel therapeutic targets and we look forward to continuing our partnership with Boehringer Ingelheim to best address difficult-to-treat cancers.”
In addition to the programs in the partnership with Boehringer Ingelheim, OBT’s clinical assets have also been enabled through the OGAP® discovery platform. Selecting the right target is fundamental for the successful development of a truly first-in-class oncology product. OBT’s platforms are designed to discover novel therapeutic targets and engineer antibodies to those targets, including CAR-T, other T-cell and NK cell-mediated cytotoxicity (ADCC) therapeutics to best address difficult-to-treat cancers. A major differentiator between OBTs discovery platform and other approaches is the retention of the link between individual patient samples through to the design of therapeutic antibodies and diagnostic patient selection tools, increasing the overall successful transition into clinical development.
Financial terms of the expanded agreement are not being disclosed. Under the terms of the agreement, Boehringer Ingelheim is responsible for the development and commercialization of antibody product candidates that interact with the novel targets identified by OGAP® . OBT will receive development and regulatory milestone payments and royalties on any future product sales. To date, Boehringer Ingelheim has exercised two options under the first agreement and has selected two therapeutic candidates for further development.
Boehringer Ingelheim Oncology is taking cancer on by leading the science with cancer cell directed agents, immuno-oncology therapies and their combinations to address unmet needs in lung and gastrointestinal cancers. The company invests significantly in early stage research to identify unexplored and undrugged pathways of cancer. Learn more about Boehringer Ingelheim’s innovation in oncology here .
Please click on the following link for ‘Notes to Editors’:
http://www.boehringer-ingelheim.com/press-release/collaboration-oxfordbiotherapeutics
View source version on businesswire.com: https://www.businesswire.com/news/home/20201014005517/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
72% of Organizations Have Delayed, Scaled Back or Paused AI and Edge Projects Over Resilience Concerns18.11.2026 09:01:00 CET | Press release
Organizations with embedded network resilience report outage costs $6 million lower, Opengear research finds Nearly three in four organizations (72%) have delayed, scaled back or paused an AI or edge project in the past 12 months over concerns about network resilience, according to new research from Opengear, a Digi International company (NASDAQ: DGII) (www.digi.com). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118888190/en/ 72% of Organizations Have Delayed, Scaled Back or Paused AI and Edge Projects Over Resilience Concerns The same research shows how the best-prepared organizations fare. Organizations with embedded network resilience, meaning they can reach and recover critical infrastructure when the primary network is down, reported estimated average outage costs $6 million lower over the past 12 months than organizations with less developed resilience capabilities ($12.4 million versus $18.8 million). The advanta
SWISSto12 Selects DLR GSOC as Flight Dynamics Software Partner to Support Upcoming HummingSat Satellite Missions18.11.2026 09:00:00 CET | Press release
Agreement underscores SWISSto12’s expanding relationship with key players in Germany’s space ecosystem SWISSto12, one of the world’s fastest-growing satellite and aerospace companies, today announced it has contracted the German Aerospace Center (DLR) to serve as the company’s primary flight dynamics software provider across its upcoming HummingSat GEO satellite missions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118073472/en/ SWISSto12 has selected DLR’s GSOC as its primary flight dynamics software provider for upcoming HummingSat GEO satellite missions. Under this agreement, GSOC will deliver capabilities that span orbit determination, propagation, manoeuvre planning and calibration, orbit events, antenna pointing, and long-term mission analysis. The collaboration is designed to standardise flight dynamics across SWISSto12 programmes, using a heritage European solution integrated into the company’s ground segment a
Abbove Brings European Wealth Planning Into the AI Era18.11.2026 08:05:00 CET | Press release
With the new Abbove MCP connector, advisors can now securely connect their AI tools to their clients’wealth data held in Abbove. Abbove, the European wealth planning platform used by more than 1,450 advisors serving more than 40,000 families across Europe, today launched its MCP connector. Through the open Model Context Protocol, advisors can put their clients’ complete wealth picture to work in the AI tools their institution has chosen, such as Claude, ChatGPT, Mistral or Copilot, within their access rights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117076275/en/ One question, your whole client book: your AI tool reads Abbove and shows which clients have cash coming free in the next 12 months, with dates and amounts. The difference lies in the data.AI tools are only as good as the data they consume. Abbove builds on its ability to model each family’s wealth data in a complete and structured way. Co-built by advisors
Wolters Kluwer’s Future Ready Accountant report: Redesigning work around AI is the next competitive advantage18.11.2026 06:00:00 CET | Press release
The AI adoption race is giving way to a bigger divide: firms that redesign work and those that fall behind Wolters Kluwer Tax & Accounting today released the third edition of its Future Ready Accountant report, revealing a profession operating from a position of strength but at a turning point. Based on responses from more than 2,600 accounting professionals worldwide, the report finds firms are growing, confident, and widely adopting AI. However, few have redesigned how information, workflows, and professional expertise work together. The report shows that this transformation is what will turn today’s growth into lasting value. “Adopting AI is only the first step. The real advantage comes from connecting it to how the whole firm works,” said Jason Marx, CEO, Wolters Kluwer Tax & Accounting. “This year’s Future Ready Accountant report shows the firms that pull ahead will be the ones that rethink their workflows and give their people more room to create value for clients.” The global re
Visa Expands Agentic Ready to Help Scale Trusted AI Commerce Globally18.11.2026 05:30:00 CET | Press release
Adyen, Antom, Billtrust, Checkout.com, Fiserv, Global Payments, PayPal, Stripe along with over 140 initial participants join Agentic Ready program for acceptance ecosystem.Merchants, B2B suppliers, payment providers, acquirers and commerce platforms can now join the 175+ issuers already participating in Agentic Ready across 45 markets. Visa (NYSE: V), a world leader in digital payments, today announced the expansion of the Visa Agentic Ready program to the acceptance ecosystem. As a part of Visa Intelligent Commerce, the expanded program helps merchants, payment service providers (PSPs), and acquirers prepare for agent-initiated transactions and participate in the next era of commerce. The program is launching with more than 140 participants, with additional financial institutions, merchants and enablers expected to join throughout 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117269823/en/ "Agentic commerce is alr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
